Clinical studies of DQ-2556 in surgical infections

We carried out a clinical study of DQ-2556, a newly-developed cephem antibiotic, in surgical infections. DQ-2556 was administered to 77 patients at doses of 0.5-4.0g daily for 3 to 15 days. The clinical efficacy rate was 75.7%(28/37) in peritonitis, 40.0%(2/5) in abdominal abscess, 80.0%(12/15) in b...

Full description

Saved in:
Bibliographic Details
Published inCHEMOTHERAPY Vol. 41; no. 3; pp. 392 - 410
Main Author Tanimura, Hiroshi
Format Journal Article
LanguageJapanese
Published Japanese Society of Chemotherapy 1993
Subjects
cephem
Online AccessGet full text

Cover

More Information
Summary:We carried out a clinical study of DQ-2556, a newly-developed cephem antibiotic, in surgical infections. DQ-2556 was administered to 77 patients at doses of 0.5-4.0g daily for 3 to 15 days. The clinical efficacy rate was 75.7%(28/37) in peritonitis, 40.0%(2/5) in abdominal abscess, 80.0%(12/15) in biliary tract infections, and 100%(2/2) in liver abscess. The overall efficacy rate was 74.0%(54/73). The bacteriological effect was investigated in 77 clinically isolated strains, and the overall bacterial elimination rate was 77.9%(60/77). Side effects and abnormal laboratory findings were observed in 3 of 77 patients (3.9%) and 7 of 76 patients (9.2%), respectively. These results suggest that DQ-2556 is effective against surgical infections and possesses a high degree of safety.
ISSN:0009-3165
1884-5894
DOI:10.11250/chemotherapy1953.41.392